AR050172A1 - Inhibidores de polimerasa viral - Google Patents

Inhibidores de polimerasa viral

Info

Publication number
AR050172A1
AR050172A1 ARP050102935A ARP050102935A AR050172A1 AR 050172 A1 AR050172 A1 AR 050172A1 AR P050102935 A ARP050102935 A AR P050102935A AR P050102935 A ARP050102935 A AR P050102935A AR 050172 A1 AR050172 A1 AR 050172A1
Authority
AR
Argentina
Prior art keywords
alkyl
het
6alkyl
cycloalkyl
halo
Prior art date
Application number
ARP050102935A
Other languages
English (en)
Inventor
Pierre Louis Beaulieu
Christian Brochu
Stephen Kawai
Jean Rancourt
Timothy A Stammers
Bounkham Thavonekham
Youla S Tsantrizos
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784831&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050172(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR050172A1 publication Critical patent/AR050172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), en donde: uno cualquiera de A o B es N y el otro B o A es C, en donde ôLa línea punteadaö entre dos átomos de C representa un doble enlace y ôLa línea punteadaö entre un átomo de C y un átomo de N representa un enlace sencillo; R1 es H o alquilo C1-6; R2 es alquilo C1-6, alquinilo C2-6, -C(=O)-alquiloC1-6, arilo o Het; estando arilo y Het opcionalmente sustituidos con R21; en donde R21 es uno, dos o tres sustituyentes, cada uno seleccionado independientemente de alquilo C1-6, cicloalquilo C3-7, Het, -CN, -NH2, -NHalquiloC1-6, -N(alquiloC1-6)2, halo, -O-alquiloC1-6, -S-alquiloC1-6, -SO-alquiloC1-6 y -SO2-alquiloC1-6; en donde el alquilo C1-6, -O-alquiloC1-6, -S-alquiloC1-3, -SO- alquiloC1-6 y -SO2-alquiloC1-6 está cada uno opcionalmente sustituido con uno, dos o tres sustituyentes halo; R3 es cicloalquilo C5-6, opcionalmente sustituido con uno a cuatro sustituyentes halo; R5 se selecciona de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-6-, Het y Het-alquiloC1-6-; en donde el alquilo C1-6 está opcionalmente sustituido con uno a tres sustituyentes, cada uno independientemente seleccionado de halo, ciano, alcoxi C1-6, - NHalquiloC1-6, -N(alquiloC1-6)2 y -NHSO2alquiloC1-6; y en donde cada uno de Het y la porcion Het del Het-alquiloC1-6- está opcionalmente sustituido con alquilo C1-6; y R6 se selecciona de H, alquilo C1-6 y halo; o R5 y R6 están enlazados del tal manera que el grupo de la subformula (2), es un grupo de formula (3), en donde n es 0, 1 o 2; y en donde R50 se selecciona, independientemente en cada caso, de H, halo, ciano, alcoxi C1-6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquilC3-7alquiloC1-6-, Het y Het-alquiloC1-6-; en donde el alquilo C1-6 está opcionalmente sustituido con uno a tres sustituyentes, cada uno independientemente seleccionado de halo, ciano, alcoxi C1-6, -NHalquiloC1-6, -N(alquiloC1-6)2 y - NHSO2alquiloC1-6; y en donde cada uno de Het y la porcion Het del Het-alquiloC1-6- está opcionalmente sustituido con alquilo C1-6; R7 se selecciona de H, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, -NH2, -NHalquiloC1-6, -N(alquiloC1-6)2 y halo; R9 y R10 se seleccionan, cada uno independientemente, de alquilo C1-6; o R9 y R10 están unidos covalentemente entre sí para formar cicloalquilo C3-7, cicloalquenilo C5-7 o un heterociclo de 4, 5, o 6 miembros con 1 a 3 heteroátomos, cada uno independientemente seleccionado de O, N y S; en donde el cicloalquilo, cicloalquenilo o heterociclo está opcionalmente sustituido con alquilo C1-4; en donde Het se define como un heterociclo de 4 a 7 miembros con 1 a 4 heteroátomos, cada uno seleccionado independientemente de O, N y S, que puede ser saturado, insaturado o aromático, y que opcionalmente está condensado a al menos otro ciclo para formar un heteropoliciclo de 7 a 14 miembros que tiene, en la medida de lo posible, 1 a 5 heteroátomos, cada uno independientemente seleccionado de O, N y S, siendo el heteropoliciclo satuado, insaturado o aromático; o un enantiomero, diastereoisomero o tautomero del mismo, incluida una sal, éster o un derivado del mismo.
ARP050102935A 2004-07-16 2005-07-15 Inhibidores de polimerasa viral AR050172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58867004P 2004-07-16 2004-07-16

Publications (1)

Publication Number Publication Date
AR050172A1 true AR050172A1 (es) 2006-10-04

Family

ID=35784831

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102935A AR050172A1 (es) 2004-07-16 2005-07-15 Inhibidores de polimerasa viral

Country Status (19)

Country Link
US (2) US7241801B2 (es)
EP (1) EP1771442A4 (es)
JP (1) JP2008506638A (es)
KR (1) KR20070035092A (es)
CN (1) CN1984908A (es)
AR (1) AR050172A1 (es)
AU (1) AU2005263135A1 (es)
BR (1) BRPI0513431A (es)
CA (1) CA2573210A1 (es)
EA (1) EA200700038A1 (es)
EC (1) ECSP077171A (es)
IL (1) IL180665A0 (es)
MX (1) MX2007000007A (es)
NO (1) NO20070368L (es)
PE (1) PE20060569A1 (es)
TW (1) TW200617003A (es)
UY (1) UY29017A1 (es)
WO (1) WO2006007693A1 (es)
ZA (1) ZA200609578B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0507861A (pt) * 2004-02-20 2007-07-17 Boehringer Ingelheim Int inibidores de polimerase viral
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2593450A1 (en) * 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
CN103524495A (zh) * 2005-02-11 2014-01-22 贝林格尔.英格海姆国际有限公司 2, 3-二取代的吲哚的制备方法
WO2006127289A1 (en) * 2005-05-20 2006-11-30 Valeant Research & Development Treatment of hcv with subtherapeutic doses of ribavirin
CA2618682C (en) 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007092000A1 (en) * 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
CN102872461A (zh) 2007-05-04 2013-01-16 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
JP2010533698A (ja) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
JP2010535155A (ja) * 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
US8940688B2 (en) 2007-12-05 2015-01-27 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide HCV serine protease inhibitors
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010114896A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2010132163A1 (en) 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
KR20200117065A (ko) 2010-09-21 2020-10-13 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
US9233921B2 (en) 2013-03-08 2016-01-12 The Trustees Of The University Of Pennsylvania Potent poxvirus inhibitor
CN113444047B (zh) * 2016-07-20 2023-06-16 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
NZ528644A (en) 2001-03-08 2005-05-27 Boehringer Ingelheim Ca Ltd A method for identifying a potential inhibitor of the binding between a HCV NS5B RNA-dependent RNA polymerase and an appropriate primer-template
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors

Also Published As

Publication number Publication date
EA200700038A1 (ru) 2007-08-31
ECSP077171A (es) 2007-02-28
EP1771442A1 (en) 2007-04-11
JP2008506638A (ja) 2008-03-06
MX2007000007A (es) 2007-03-07
EP1771442A4 (en) 2009-12-30
WO2006007693A1 (en) 2006-01-26
US20060052418A1 (en) 2006-03-09
UY29017A1 (es) 2006-02-24
CA2573210A1 (en) 2006-01-26
PE20060569A1 (es) 2006-06-22
IL180665A0 (en) 2007-06-03
CN1984908A (zh) 2007-06-20
BRPI0513431A (pt) 2008-05-06
US7241801B2 (en) 2007-07-10
AU2005263135A1 (en) 2006-01-26
NO20070368L (no) 2007-01-30
KR20070035092A (ko) 2007-03-29
TW200617003A (en) 2006-06-01
ZA200609578B (en) 2008-08-27
US20070249629A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AR050172A1 (es) Inhibidores de polimerasa viral
AR047706A1 (es) Inhibidores de polimerasa viral
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR076775A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
ES2531315T3 (es) Compuestos de fosfinato antivíricos
CO5580777A2 (es) Inhibidores de hidroxipirimidinona carboxamida n-sustituidos de vih integrasa
AR073136A1 (es) Compuestos de pirrol
AR069335A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
AR078875A2 (es) Compuesto uracilo composicion herbicida que lo comprende, metodo para controlar malezas con el mismo, su uso.
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR069832A1 (es) Inhibidores de la polimerasa virica
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
ES2352576T3 (es) Inhibidiores de la replicación del virus de la inmunodeficiencia humana.
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR057209A1 (es) Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
AR087148A1 (es) Imidazopiridazinas
AR073397A1 (es) Derivados de (r) -3- (n,n-dimetilamino) pirrolidina
AR077215A1 (es) Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos
AR060438A1 (es) 2-(piridin-2-il) - pirimidinas como fungicidas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure